Roxbury Financial’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.1K Hold
563
0.02% 273
2026
Q1
$18K Buy
563
+120
+27% +$3.91K 0.02% 269
2025
Q4
$15.5K Buy
443
+119
+37% +$4.33K 0.01% 271
2025
Q3
$9.21K Buy
324
+60
+23% +$1.44K 0.01% 293
2025
Q2
$4.78K Buy
264
+195
+283% +$3.56K ﹤0.01% 310
2025
Q1
$1.45K Buy
+69
New +$1.53K ﹤0.01% 330

Other funds holding NAMS

Roxbury Financial's NAMS Position: Q2 2026 in Review

Roxbury Financial held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 563 shares worth $19.1K. The position accounts for 0.02% of the portfolio, ranked #273.

Roxbury Financial first reported a position in NAMS in Q1 2025 and has held it in 6 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Roxbury Financial held 563 shares of NewAmsterdam Pharma worth $19.1K as of Q2 2026.
  • Roxbury Financial left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up 0.02% of Roxbury Financial's portfolio in Q2 2026, its #273 holding.
  • Roxbury Financial first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 6 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Roxbury Financial's 13F filing for Q2 2026, filed 1 Jul 2026.